[Correspondence] Ovarian cancer screening: UKCTOCS trial
UKCTOCS (March 5, p 945)1 was an expensive (£17 million), well designed, and well executed screening trial with a solid and convincing negative conclusion based on its previous primary endpoints. It was surprising that the peer reviewers allowed the authors to include the secondary data-driven analysis (excluding prevalent cases) in the main trial report. But it was shocking that the Lancet Editors allowed this secondary post-hoc analysis to be included in the abstract and in the press release. The absence of difference in all-cause mortality was reported only in the appendix.